Revenue
2019
2020
2021
2022
2023
2024
2025
Maravai Lifesciences Holdings, Inc. (MRVI)
Price$7.32Cached quote
Net income
2019
2020
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 · Dec 31 | 2020 · Nov 19 | 2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $185.7M | $259.2M | $288.9M | $883.0M | $799.2M | $284.1M | — | $143.1M |
| Gross profit | $34.0M | $108.3M | $140.2M | $714.0M | $658.7M | $204.4M | — | $76.3M |
| Gross margin | 18.30% | 41.79% | 48.52% | 80.87% | 82.41% | 71.96% | — | 53.30% |
| Research & development | $17.4M | $19.2M | $17.3M | $18.4M | $15.2M | $9.3M | — | $3.6M |
| Operating expenses | $249.3M | $494.8M | $320.6M | $308.8M | $244.6M | $164.2M | — | $119.2M |
| Operating income | −$215.3M | −$235.6M | −$31.6M | $574.2M | $554.6M | $119.9M | — | $24.0M |
| Operating margin | −115.89% | −90.91% | −10.95% | 65.03% | 69.40% | 42.20% | — | 16.76% |
| EBITDA | −$163.8M | −$187.2M | $8.6M | $606.1M | $579.4M | $145.8M | — | $48.1M |
| EBITDA margin | −88.16% | −72.24% | 2.98% | 68.64% | 72.49% | 51.33% | — | 33.58% |
| Net income | −$130.8M | −$144.8M | −$119.0M | $220.2M | $182.0M | $89.0M | $88.2M | −$4.5M |
| Net profit margin | −70.41% | −55.89% | −41.19% | 24.94% | 22.78% | 31.32% | — | −3.12% |
| Basic EPSper basic share | -$0.90 | -$1.05 | -$0.90 | $1.67 | $1.59 | $7.43 | — | -$0.03 |
| Diluted EPSper diluted share | -$0.90 | -$1.05 | -$0.90 | $1.67 | $1.56 | $2.36 | — | -$0.03 |
Owners
Reported shareholders
13.53%of listed shares
GTCR LLC20.15M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
GTCR LLC | 13.53%20.15M shares |
BlackRock, Inc. | 6.70%9.97M shares |
BRAIDWELL LP | 5.85%8.7M shares |
First Eagle Investment Management, LLC | 4.93%7.34M shares |
12 West Capital Management LP | 4.74%7.06M shares |
MILLENNIUM MANAGEMENT LLC | 4.37%6.51M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.55%5.28M shares |
Ophir Asset Management Pty Ltd | 3.24%4.83M shares |
RENAISSANCE TECHNOLOGIES LLC | 3.09%4.61M shares |
DEUTSCHE BANK AG\ | 2.89%4.3M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.10%3.13M shares |
STATE STREET CORP | 1.95%2.9M shares |
Nuveen, LLC | 1.92%2.86M shares |
JPMORGAN CHASE & CO | 1.74%2.59M shares |
TWO SIGMA INVESTMENTS, LP | 1.52%2.26M shares |
Monaco Asset Management SAM | 1.50%2.23M shares |
PRUDENTIAL FINANCIAL INC | 1.45%2.15M shares |
CITADEL ADVISORS LLC | 1.43%2.12M shares |
Brust Bernd | ≈1.42%2.12M shares |
Point72 Asset Management, L.P. | 1.35%2.01M shares |
Percentages use 148.89M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 10, 2026Form 4 · 10b5-1 | ORESHACK KURTGeneral Counsel | SellClass A Common Stock | 25.0K | $5.10 | $127.5K | 335.8K |
| Jun 9, 2026Form 4 · 10b5-1 | ORESHACK KURTGeneral Counsel | SellClass A Common Stock | 25.0K | $5.06 | $126.5K | 360.8K |
| Dec 8, 2025Form 4 | LUCIER GREGORY TDirector | BuyClass A Common Stock | 48.5K | $3.67 | $178.1K | 155.1K |
| Dec 5, 2025Form 4 | LUCIER GREGORY TDirector | BuyClass A Common Stock | 51.5K | $3.70 | $190.4K | 106.6K |
| Nov 13, 2025Form 4 | Brust BerndChief Executive Officer | BuyClass A Common Stock · indirect | 216.2K | $3.25 | $702.7K | 466.8K |